ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study-Reference-Cited by-同舟云学术

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study

Published:2018-09-06 Issue:2 Volume:104 Page:e65-e67
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Strati Paolo,Fanale Michelle A.,Oki Yasuhiro,Turturro Francesco,Fayad Luis E,Bartlett Nancy L.,Gladstone Douglas E.,Kasamon Yvette L.,Portlock Carol S.,Wilson Wyndham H.,Goy Andre,Younes Anas,Lee Hun Ju

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical relevance and therapeutic implications of CD20 expression in Hodgkin's lymphoma;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

2. Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances;International Journal of Molecular Sciences;2023-06-13

3. Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy;Critical Reviews in Oncology/Hematology;2023-02

4. CD20 expression is closely associated with Epstein–Barr virus infection and an inferior survival in nodular sclerosis classical Hodgkin lymphoma;Frontiers in Oncology;2022-09-06

5. Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial;Journal for ImmunoTherapy of Cancer;2022-05